Cargando…

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

BACKGROUND: Activating mutation of KRAS and BRAF are focused on as potential prognostic and predictive biomarkers in patients with colorectal cancer (CRC) treated with anti-EGFR therapies. This study investigated the clinicopathological features and prognostic impact of KRAS/BRAF mutation in advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokota, T, Ura, T, Shibata, N, Takahari, D, Shitara, K, Nomura, M, Kondo, C, Mizota, A, Utsunomiya, S, Muro, K, Yatabe, Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048210/ https://www.ncbi.nlm.nih.gov/pubmed/21285991 http://dx.doi.org/10.1038/bjc.2011.19

Ejemplares similares

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications
por: Shitara, Kohei, et al.
Publicado: (2010)

Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer
por: Wallin, U, et al.
Publicado: (2011)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level
por: Sakaizawa, K, et al.
Publicado: (2012)

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression
por: Lin, J, et al.
Publicado: (2011)

Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence
por: Letellier, Elisabeth, et al.
Publicado: (2017)

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
por: Heinzerling, L, et al.
Publicado: (2013)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
por: Ino, K, et al.
Publicado: (2006)

Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients
por: Rawson, J B, et al.
Publicado: (2011)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Disseminated tumour cells as a prognostic biomarker in colorectal cancer
por: Flatmark, K, et al.
Publicado: (2011)

Prognostic significance of CD44 variant 2 upregulation in colorectal cancer
por: Ozawa, M, et al.
Publicado: (2014)

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
por: Zuidervaart, W, et al.
Publicado: (2005)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
por: Board, R E, et al.
Publicado: (2009)

MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening
por: Iehara, T, et al.
Publicado: (2006)

The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer
por: Talieri, M, et al.
Publicado: (2009)

Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
por: Gordziel, C, et al.
Publicado: (2013)

Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer
por: Matsumura, T, et al.
Publicado: (2015)

Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma
por: Kontos, C K, et al.
Publicado: (2010)

Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients
por: Hosono, S, et al.
Publicado: (2007)

Expression and prognostic value of transcription factor PROX1 in colorectal cancer
por: Skog, M, et al.
Publicado: (2011)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer
por: Eberhard, J, et al.
Publicado: (2012)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer
por: Chen, Z-Y, et al.
Publicado: (2015)

Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients
por: Mizuno, M, et al.
Publicado: (2015)

BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
por: Lee, Y-K, et al.
Publicado: (2009)

Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia
por: Malesci, A, et al.
Publicado: (2014)

Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival
por: Ino, K, et al.
Publicado: (2006)

Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer
por: Baba, Y, et al.
Publicado: (2010)

β(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients
por: Shrout, J, et al.
Publicado: (2008)

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
por: van Grieken, N C T, et al.
Publicado: (2013)

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
por: Saridaki, Z, et al.
Publicado: (2015)

A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma
por: Lo, Michelle Chin I, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0os475lduf54bqfovmakeve3mg